Chemotherapy News and Research

Latest Chemotherapy News and Research

New drug cocktails make targeted cancer therapies more efficient with less side effects

Mount Sinai researchers have discovered that certain drug cocktails help targeted therapies attack cancer more efficiently while lessening common side effects, according to a study published today in Cancer Research.

1 Aug 2018

BRAF inhibitors may be effective at treating rare ovarian cancer, study shows

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

30 Jul 2018

$Researchers use magnetic surgical cement for spinal fractures and targeted drug delivery$

Researchers use magnetic surgical cement for spinal fractures and targeted drug delivery

Patients with spinal fractures caused by tumors or osteoporosis usually undergo a procedure called kyphoplasty, where the fracture is filled with surgical cement.

28 Jul 2018

Answer to decades-old mystery may allow some children to avoid bone marrow transplantation

Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder.

27 Jul 2018

Researchers develop nano-carriers to specifically target senescent cells

Senescent cells are damaged cells that do not perform their normal roles anymore but that are not dead -hence they are commonly known as zombi cells.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

New combination approach may help crush resistance to treatment in lung cancer patients

New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Study: Blood test can predict response of advanced prostate cancer patients to treatments

An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.

25 Jul 2018

New protein complex may explain why patients develop resistance to novel anti-cancer drugs

A team of researchers at the University of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.

25 Jul 2018

Environment could be important battle ground in the global fight against antibiotic resistance

The environment could be as important a battle ground as the clinic in the global fight against the spread of antibiotic resistance, new research has shown.

24 Jul 2018

'Hijacked' cell response to stress reveals potential therapeutic targets for leukemia

A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows.

24 Jul 2018

Researchers shed light on risks presented by residual disease for younger breast cancer patients

A new study from the Stanford Cancer Institute finds that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive tumor (pathologic complete response).

23 Jul 2018

Mysterious molecule Yin Yang may fuel tumor growth in breast cancer

Scientists have unveiled clues about a mysterious molecule called Yin Yang1 - and revealed it may fuel tumor growth in breast cancer.

23 Jul 2018

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.

23 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

Replacing conventional cancer treatment with complementary therapy linked to increased risk of death

People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine.

20 Jul 2018

Chemotherapy News and Research

Latest Chemotherapy News and Research

New drug cocktails make targeted cancer therapies more efficient with less side effects

BRAF inhibitors may be effective at treating rare ovarian cancer, study shows

Researchers use magnetic surgical cement for spinal fractures and targeted drug delivery

Answer to decades-old mystery may allow some children to avoid bone marrow transplantation

Researchers develop nano-carriers to specifically target senescent cells

CNDA approves KEYTRUDA for treatment of advanced melanoma

New combination approach may help crush resistance to treatment in lung cancer patients

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Study: Blood test can predict response of advanced prostate cancer patients to treatments

New protein complex may explain why patients develop resistance to novel anti-cancer drugs

Environment could be important battle ground in the global fight against antibiotic resistance

'Hijacked' cell response to stress reveals potential therapeutic targets for leukemia

Researchers shed light on risks presented by residual disease for younger breast cancer patients

Mysterious molecule Yin Yang may fuel tumor growth in breast cancer

Pfizer announces FDA approval of biosimilar to Neupogen

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

Replacing conventional cancer treatment with complementary therapy linked to increased risk of death

Genetic sequencing reveals new clues to aggressiveness of prostate cancer

Study uncovers new protein complex that shields broken DNA ends

Understanding triple-negative breast cancer to develop better treatments

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in